11:35 AM EST - Nuvo Research Inc. : and Paladin Labs Inc., a leading specialty pharmaceutical company, announced today that they have entered into a license and supply agreement granting Paladin exclusive Canadian rights to market and sell Synera®, upon regulatory approval. Synera is a topical patch that combines lidocaine, tetracaine and heat, using Nuvo's proprietary "Controlled Heat Assisted Drug Delivery" (CHADD) technology. Nuvo Research Inc.
shares T.NRI are trading up $0.01 at $0.10.
